Adding Durvalumab to BCG Prevents Recurrence in High-Risk Bladder Cancer
In this article
High-risk non-muscle-invasive bladder cancer (NMIBC) is among uro-oncology's toughest challenges. Standard BCG—the tuberculosis vaccine—after TURBT cannot prevent recurrence or progression in a substantial proportion of patients. When BCG fails, patients often face radical cystectomy, removal of the bladder.
The POTOMAC studywas designed to address this unmet need: could adding the PD-L1 inhibitor Durvalumab to BCG activate immunity more strongly and prevent recurrence?
1. POTOMAC Study Design
This open-label, randomized phase 3 trial involved patients from 12 countries: 1,018 patients , all previously treated with TURBT, BCG-naive, and diagnosed with high-risk NMIBC.
Patients were randomized 1:1:1 to three arms:
2. Results: The Power of Immunotherapy
After a median 60.7 months (5 years) of follow-up, results for the primary endpoint, disease-free survival (DFS), were reported.
DISEASE-FREE SURVIVAL AT MONTH 24
A Notable Negative Finding: Group 2 (Durva + Short BCG) failed to outperform standard treatment (HR 1.14). This demonstrated that maintenance BCG—long-term use—is essential for synergy with immunotherapy.
Safety Profile
| Adverse Effect | Group 1 (Combination) | Group 3 (BCG) |
|---|---|---|
| Grade 3-4 (Severe) Adverse Effects | 21% | 4% |
| Serious Immune-Related Adverse Effects | 13% | 4% |
*Dysuria—burning during urination—was the most common effect in both groups. No treatment-related deaths occurred.
Original Article
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.
The "Combination Era" Begins in Bladder Cancer
POTOMAC is more than a statistical success: it is biological proof. For years, we asked what to do when BCG fails. This study suggests supporting BCG with a powerful checkpoint inhibitor such as durvalumab may change outcomes, particularly in high-risk patients.
However, cost and toxicity must be carefully balanced. A 32% risk reduction is invaluable, but severe toxicity in 21% versus 4% with BCG requires close monitoring. The protocol has strong potential to become standard in selected, very-high-risk patients likely to need cystectomy.